Adjuvant Albumin-bound Paclitaxel Versus Taxanes in Breast Cancer: a Real-world Study

Inclusion Criteria: 1. Female patients aged from 18 to 70 years old; 2. Histologically confirmed as invasive breast cancer; 3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; 4. Participants achieved complete tumor resection by radical mastectomy, modified radical mastectomy or breast-conserving surgery with negative margins; 5. AC-T adjuvant chemotherapy is planned after breast cancer surgery; 6. Participants with HER-2 negative breast cancer at high risk of recurrence who meet any of the following conditions: 1) HR positive, and ≥4 positive lymph nodes or 1-3 positive lymph nodes with other risk of recurrence \[such as high Ki67 expression (≥20%), T \> 2 cm, age \< 35 years, lymphovascular invasion, grade 3 histology\]; 2) HR negative with positive lymph node or T \> 2 cm; 7. LVEF ≥ 50%; 8. Participants had good compliance with the planned treatment and follow-up, understood the study procedures of this study, and signed informed consent form. Exclusion Criteria: 1. In the past and present, participants with severe cardiac disease or discomfort , including but not limited: 1) High-risk uncontrolled arrhythmia, atrial tachycardia (heart rate \> 100/min in resting state), significant ventricular arrhythmia (ventricular arrhythmia) or higher atrioventricular block (second-degree type 2 \[Mobitz 2\] atrioventricular block or third-degree atrioventricular block); 2) Angina pectoris requiring anti-angina medication; 3) Clinically significant valvular heart disease; 4) ECG showing transmural myocardial infarction; 5) Uncontrolled hypertension (eg systolic blood pressure \> 180mm Hg or diastolic blood pressure \> 100mmHg); 6) Myocardial infarction; 7) Congestive heart failure; 2. Participants who have received prior any systematic treatment for breast cancer; 3. Participants with bilateral invasive breast cancer; 4. Breast cancer with distant metastasis; 5. Grade 2 or higher Sensory or motor neurotoxicity was present as assessed by CTCAE V5.0; 6. Participants have the following serious illnesses or medical conditions, including but not limited: 1) History of serious neurological or psychiatric disorders, including psychosis, dementia, or epilepsy, that prevent understanding and informed consent; 2) Active uncontrolled infection; 3) Active peptic ulcer, unstable diabetes; 7. Previous or current existence of other malignant tumors other than breast cancer; 8. Severe liver and kidney dysfunction; 9. The presence of any myelodysplastic and other hematopoietic disorders; 10. Participants who are known to be allergic to the active or other components of the study treatment; 11. Participants who are pregnant, breastfeeding, or refuse to use adequate contraception prior to study entry and for the duration of study participation; 12. Participants who were judged by the investigator to be unsuitable for this study.